<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2002-70</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-413</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>ТЕРАПИЯ АНТИМАЛЯРИЙНЫМИ (АМИНОХИНОЛИНОВЫМИ) ПРЕПАРАТАМИ И БЕЗОПАСНОСТЬ ОРГАНА ЗРЕНИЯ</article-title><trans-title-group xml:lang="en"><trans-title>THERAPY BY ANTIMALARIA (AMINOOUINOLINE) DRUGS AND OF OCULAR SAFETY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Mouraviev</surname><given-names>Yu. V.</given-names></name><name name-style="western" xml:lang="en"><surname>Mouraviev</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Turgieva</surname><given-names>E P</given-names></name><name name-style="western" xml:lang="en"><surname>Turgieva</surname><given-names>E P</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2002</year></pub-date><pub-date pub-type="epub"><day>15</day><month>04</month><year>2002</year></pub-date><volume>40</volume><issue>2</issue><issue-title>№2 (2002)</issue-title><fpage>3</fpage><lpage>3</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Mouraviev Y.V., Turgieva E.P., 2002</copyright-statement><copyright-year>2002</copyright-year><copyright-holder xml:lang="ru">Mouraviev Y.V., Turgieva E.P.</copyright-holder><copyright-holder xml:lang="en">Mouraviev Y.V., Turgieva E.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/413">https://rsp.mediar-press.net/rsp/article/view/413</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;НасоновЕ.Л. Антималяриииые (амииохниолииовые) препараты: новые фармакологические свойства и перспективы клинического применения. Клииич фармакол. и тер., 1998, 3, 65-68.&lt;/p&gt;&lt;p&gt;Arden G.B. Kolb Н, Antimalarial therapy and early retinal changes ill patients with rheumatoid arthritis. Br. Med. J., 1966. I. 270-273.&lt;/p&gt;&lt;p&gt;Aylward J.M, Hydroxychloroquine and chloroquine: assessing the risk of the toxi-city. J. Am. Ophtlalmol, Assoc., 1993, 64, 787-797.&lt;/p&gt;&lt;p&gt;Bartholomew L.E., DufT I.F.Amopyroquine (Propoquin) in rheumatoid arthritis. Arthr. Rheum., 1963, 6, 356-3634.&lt;/p&gt;&lt;p&gt;Berliner R.W., Earle D., Taggcrt J. et al. Studies on the chemotherapy of human malarias. VI The physiological deposition, antimalarial activity and toxicity of several derivatives of 4-aminoquinolines. J. Clin. Invest., 1948, 27 (suppl.), 60.&lt;/p&gt;&lt;p&gt;BernstcinH.N., Ginsberg.[.The pathology of chloroquine retinopathy. Arch. Ophtalmol., 1964, 71, 238.&lt;/p&gt;&lt;p&gt;Bienfang D., Coblyn J.S., Liang M.H., Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation - a consecutive series. J.Rheumatol., 2000, 27, 2703-2706.&lt;/p&gt;&lt;p&gt;Blyth C. Lane C, Hydroxychloroquine retinopathy; is screening necessary? Br Med.J., 1998, 916, 710-727.&lt;/p&gt;&lt;p&gt;Burns R, Delayed oncet of chloroquine retinopathy, N. Engl. J. Med,, 1966, 275, 693-696. 10. Butler I.Retinopathy following the use of chloroquin and allied substanecs. Ophtalmol., 1965, 149, 204-206. 11. Cambioggi A.Unusual ocular lesions in a case lupus erithematosis. Arch. Ophthalmol., 1957, 57, 551-453. 12. Carr R.E., Gouras P., Gunkel O.D. Chloroquine retinopathy. Arch. Ophtalmol., 1966, 75, 171-178. 13. Carr R.E.. Henkind P., Rothfield N., Siegel I.M. Ocular toxicity of anlimalarial drugs: long-term follow-up Am.J. Ophthalmol., 1968, 66, 738-744. 14. Crews S.J. Chloroquine retinopathy with recover)' in early stages. Lancet, 1964, 2. 436-438. 15. Easterbrook M. Detection and prevention of maculopathy associated with anlimalarial agents. Int. Ophtalmol. Clin., 1999, 39, 49-57&lt;/p&gt;&lt;p&gt;Easterbrook M.En Ophtalmological view on the efficacy and safety of chloroquine versus hydrochloroquine. J.Rheumatol., 1999^ 26. 1866-1867.&lt;/p&gt;&lt;p&gt;Easterbrook M.Is corneal deposition of anlimalarial any indication of retinal toxilicy? Can. J, Ophthalmol., 1990, 25, 249-251.&lt;/p&gt;&lt;p&gt;Elkington J.R., Hulh EJ.Letters and comments: chloroquine in rheumatoid arthritis. Ann.Intern.Med., 1965, 62, 1066-1067.&lt;/p&gt;&lt;p&gt;Falcone М., Paolini L., Lou L. Hydroxychloroquine toxicity despite normal dose therapy. Ann.Ophlhalmol., 1993, 25. 385388.&lt;/p&gt;&lt;p&gt;Freedman A., Steinberg L.Chloroquine in rheumatoid arthritis: A double-blind folfd trial of treatment for one year. Ann.Rheum.Dis., 1960, 19, 243-250.&lt;/p&gt;&lt;p&gt;Gruess A.F., Schachet A., Nicholl J.et al. Chloroquine retinopathy: is fluorescein angiography necessary1? Ophthalmol., 1985, 92, 1127-1129.&lt;/p&gt;&lt;p&gt;Hobbs H.E., Sorsby Д., Freedman A. Reinopathy following chloroquine therapy. Lancet, 1959, 2, 478-480.&lt;/p&gt;&lt;p&gt;Hollander J.L. The calculated risk of arthritis treatment. Ann. Intern. Med., 1965, 62. 1062-1064.&lt;/p&gt;&lt;p&gt;Levy G.D. Munz S.J., Paschal J.et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenier outpatient practice. Arthr. Rheum., 1997, 40, 14821486.&lt;/p&gt;&lt;p&gt;Mackenzie A.H. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am. J.Med,, 1983, 75, 40-45.&lt;/p&gt;&lt;p&gt;Mavrikukis М., Papazoglon S„ Saikiakis H. el al. Retinal toxicity in long term hydroxychloroquine treatment. Ann.Rheum.Dis., 1996, 55, 187-i89. '&lt;/p&gt;&lt;p&gt;Morand E.F., McCloud I., Littejohn G.O. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum.Dis, 1992, 51, 1318-1321.&lt;/p&gt;&lt;p&gt;Morsman C.D.G., Liversey S.J., Richards I.M. el al.Screening for hydroxychloroquine retinal toxicily: is it necessary? Eye, 1990, 4, 572-576.&lt;/p&gt;&lt;p&gt;Nylander U.Ocular damage in chloroquine therapy. Acta Ophtalmol., 1966, 44, 335-348.&lt;/p&gt;&lt;p&gt;Okun G., Gouras , Bernstein H., Von Sallman L. Chloroquine retinopathy. Arch. Ophttalmol., 1963, 69, 59-71. Ophtalmol., 1964, 71, 157-165.&lt;/p&gt;&lt;p&gt;Percival S. B., Berhman J. Ophlhalmological safety of chloroquine. Br.J.Ophttalmol. 1969. 53, 101-109.&lt;/p&gt;&lt;p&gt;Percival S. В., Meanock I. Chloroquine: ophlhalmological safety, and clinical assessmenl in rheumatoid arthritis. Br.Med.J., 1968, 3, 579-584.&lt;/p&gt;&lt;p&gt;Popert A.J. Meyers K.A.E., Sharp J. Chloroquine diphosphate in rheumatoid arthritis, a controlled trial. Ann. Rheum. Dfis., 1961, 20, 18-35.&lt;/p&gt;&lt;p&gt;Puavilai S. Kunavisarut S., Vatanasuk M. el al.Ocular loxicily of chloroquin among Thai palients. Inl.J.Dermatol., 1999, 38, 934-937.&lt;/p&gt;&lt;p&gt;Raines M.F., Bhargava S.K., Rosea G.S. The blood-retinnal barrier in chloroquine retinopalhy. Invest. Ophttalmol., Vis.Sci^ 1998, 30, 1726-1731.&lt;/p&gt;&lt;p&gt;Reynes R.I., Kronel G. Falbo A. et al. Ophtlalmologic safely of long-term hydroxychloroquine treatment. Arthritis Rheum , 1979. 22, 832-836.&lt;/p&gt;&lt;p&gt;Reynes R.l. Ophtalmologic considerations in using antimalarials in the Uniled States. Lupus, 1996, 5, suppl 1, 73-74. 3S. Rynes R.Antimalarial drugs. In: Textbook of rheumatology, ed. W.Kelley, E.Harris, S.Ruddy, C.Sledge, W.B.Saunders. 1993. 731-742.&lt;/p&gt;&lt;p&gt;Royal College of OpIUtalmologists. Ocular toxicily and hydroxychloroquine. Guidelines for screening. 1998.&lt;/p&gt;&lt;p&gt;Rubin M.L., Thomas W.C. Diplopia and loss of accommodation due to chloroquine. Arthr. Rheum., 1970, 13, 75.&lt;/p&gt;&lt;p&gt;Ruiz R.S., Saatei O.A. Chloroquine and hydroxychloroquine relinopalhy: how to follow affected patients. Ann. Ophthalmol., 1991, 23, 290-291.&lt;/p&gt;&lt;p&gt;Sachs D.D., Hoban M.J. Engleinan E. Chorioretinopathy induced by chronic administration of chloroquine phosphate. Arthritis Rheum., 1962, 5, 318-319.&lt;/p&gt;&lt;p&gt;Sassman F.W., Cassidy J.T., Alpern М., Maaseidvaag Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine. Am. J. Ophtalmol., 1970, 71, 515-523.&lt;/p&gt;&lt;p&gt;Scherbel A.L., Mackenzie A.H., Nousek J.E., Aidjian M.Ocular lesions in rheumatoid arthritis and related disorders wilh particular reference to retinopalhy: a study of 741 patients treated with and without chloroquine drugs. N. Engl. J. Med. 1965, 273, 360-366.&lt;/p&gt;&lt;p&gt;Shipley M„ Silman A.Should patients on hydroxychloroquine have their eyes examined regularly? Bril. J.Rheumatol., 1997, 36, 514-515.&lt;/p&gt;&lt;p&gt;Tobin D.R., Krohel G.B., Reynes R.I.: Hydroxychloroquine. A seven-year experience. Arch. Ophtalmol., 1982, 100, 478.&lt;/p&gt;&lt;p&gt;Voipio H.Incidence of chloroquine relinopalhy. Acta Ophthalmol., 1966, 44, 349-354.&lt;/p&gt;&lt;p&gt;Vu B.L., Easterbrook М., Hovis J.K. Detection of color vision defects in chloroquine retinopalhy. Ophtalmol., 1999, 106, 17991803.&lt;/p&gt;&lt;p&gt;Wallace D.J.Antimalarial therapies. In: Wallace D.J., Hahn B. H., eds. Dubois'Lupus Erythematosus, 4th edn. Philadelphia: Lea&amp;amp;Febiger, 1993, 563-573.&lt;/p&gt;&lt;p&gt;Weise E.E., Yarronzzi L.A. Ring maculopathies mimicking chloroquine retinopalhy. Am.J.Ophlalmol., 1974, 78, 204-210.&lt;/p&gt;&lt;p&gt;Young , Rardin Т., Lankford B. et al. The apparent elimination of chloroquine retinopathy. Arthr. Rheum., 1974, 15, 464.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;НасоновЕ.Л. Антималяриииые (амииохниолииовые) препараты: новые фармакологические свойства и перспективы клинического применения. Клииич фармакол. и тер., 1998, 3, 65-68.&lt;/p&gt;&lt;p&gt;Arden G.B. Kolb Н, Antimalarial therapy and early retinal changes ill patients with rheumatoid arthritis. Br. Med. J., 1966. I. 270-273.&lt;/p&gt;&lt;p&gt;Aylward J.M, Hydroxychloroquine and chloroquine: assessing the risk of the toxi-city. J. Am. Ophtlalmol, Assoc., 1993, 64, 787-797.&lt;/p&gt;&lt;p&gt;Bartholomew L.E., DufT I.F.Amopyroquine (Propoquin) in rheumatoid arthritis. Arthr. Rheum., 1963, 6, 356-3634.&lt;/p&gt;&lt;p&gt;Berliner R.W., Earle D., Taggcrt J. et al. Studies on the chemotherapy of human malarias. VI The physiological deposition, antimalarial activity and toxicity of several derivatives of 4-aminoquinolines. J. Clin. Invest., 1948, 27 (suppl.), 60.&lt;/p&gt;&lt;p&gt;BernstcinH.N., Ginsberg.[.The pathology of chloroquine retinopathy. Arch. Ophtalmol., 1964, 71, 238.&lt;/p&gt;&lt;p&gt;Bienfang D., Coblyn J.S., Liang M.H., Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation - a consecutive series. J.Rheumatol., 2000, 27, 2703-2706.&lt;/p&gt;&lt;p&gt;Blyth C. Lane C, Hydroxychloroquine retinopathy; is screening necessary? Br Med.J., 1998, 916, 710-727.&lt;/p&gt;&lt;p&gt;Burns R, Delayed oncet of chloroquine retinopathy, N. Engl. J. Med,, 1966, 275, 693-696. 10. Butler I.Retinopathy following the use of chloroquin and allied substanecs. Ophtalmol., 1965, 149, 204-206. 11. Cambioggi A.Unusual ocular lesions in a case lupus erithematosis. Arch. Ophthalmol., 1957, 57, 551-453. 12. Carr R.E., Gouras P., Gunkel O.D. Chloroquine retinopathy. Arch. Ophtalmol., 1966, 75, 171-178. 13. Carr R.E.. Henkind P., Rothfield N., Siegel I.M. Ocular toxicity of anlimalarial drugs: long-term follow-up Am.J. Ophthalmol., 1968, 66, 738-744. 14. Crews S.J. Chloroquine retinopathy with recover)' in early stages. Lancet, 1964, 2. 436-438. 15. Easterbrook M. Detection and prevention of maculopathy associated with anlimalarial agents. Int. Ophtalmol. Clin., 1999, 39, 49-57&lt;/p&gt;&lt;p&gt;Easterbrook M.En Ophtalmological view on the efficacy and safety of chloroquine versus hydrochloroquine. J.Rheumatol., 1999^ 26. 1866-1867.&lt;/p&gt;&lt;p&gt;Easterbrook M.Is corneal deposition of anlimalarial any indication of retinal toxilicy? Can. J, Ophthalmol., 1990, 25, 249-251.&lt;/p&gt;&lt;p&gt;Elkington J.R., Hulh EJ.Letters and comments: chloroquine in rheumatoid arthritis. Ann.Intern.Med., 1965, 62, 1066-1067.&lt;/p&gt;&lt;p&gt;Falcone М., Paolini L., Lou L. Hydroxychloroquine toxicity despite normal dose therapy. Ann.Ophlhalmol., 1993, 25. 385388.&lt;/p&gt;&lt;p&gt;Freedman A., Steinberg L.Chloroquine in rheumatoid arthritis: A double-blind folfd trial of treatment for one year. Ann.Rheum.Dis., 1960, 19, 243-250.&lt;/p&gt;&lt;p&gt;Gruess A.F., Schachet A., Nicholl J.et al. Chloroquine retinopathy: is fluorescein angiography necessary1? Ophthalmol., 1985, 92, 1127-1129.&lt;/p&gt;&lt;p&gt;Hobbs H.E., Sorsby Д., Freedman A. Reinopathy following chloroquine therapy. Lancet, 1959, 2, 478-480.&lt;/p&gt;&lt;p&gt;Hollander J.L. The calculated risk of arthritis treatment. Ann. Intern. Med., 1965, 62. 1062-1064.&lt;/p&gt;&lt;p&gt;Levy G.D. Munz S.J., Paschal J.et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenier outpatient practice. Arthr. Rheum., 1997, 40, 14821486.&lt;/p&gt;&lt;p&gt;Mackenzie A.H. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am. J.Med,, 1983, 75, 40-45.&lt;/p&gt;&lt;p&gt;Mavrikukis М., Papazoglon S„ Saikiakis H. el al. Retinal toxicity in long term hydroxychloroquine treatment. Ann.Rheum.Dis., 1996, 55, 187-i89. '&lt;/p&gt;&lt;p&gt;Morand E.F., McCloud I., Littejohn G.O. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum.Dis, 1992, 51, 1318-1321.&lt;/p&gt;&lt;p&gt;Morsman C.D.G., Liversey S.J., Richards I.M. el al.Screening for hydroxychloroquine retinal toxicily: is it necessary? Eye, 1990, 4, 572-576.&lt;/p&gt;&lt;p&gt;Nylander U.Ocular damage in chloroquine therapy. Acta Ophtalmol., 1966, 44, 335-348.&lt;/p&gt;&lt;p&gt;Okun G., Gouras , Bernstein H., Von Sallman L. Chloroquine retinopathy. Arch. Ophttalmol., 1963, 69, 59-71. Ophtalmol., 1964, 71, 157-165.&lt;/p&gt;&lt;p&gt;Percival S. B., Berhman J. Ophlhalmological safety of chloroquine. Br.J.Ophttalmol. 1969. 53, 101-109.&lt;/p&gt;&lt;p&gt;Percival S. В., Meanock I. Chloroquine: ophlhalmological safety, and clinical assessmenl in rheumatoid arthritis. Br.Med.J., 1968, 3, 579-584.&lt;/p&gt;&lt;p&gt;Popert A.J. Meyers K.A.E., Sharp J. Chloroquine diphosphate in rheumatoid arthritis, a controlled trial. Ann. Rheum. Dfis., 1961, 20, 18-35.&lt;/p&gt;&lt;p&gt;Puavilai S. Kunavisarut S., Vatanasuk M. el al.Ocular loxicily of chloroquin among Thai palients. Inl.J.Dermatol., 1999, 38, 934-937.&lt;/p&gt;&lt;p&gt;Raines M.F., Bhargava S.K., Rosea G.S. The blood-retinnal barrier in chloroquine retinopalhy. Invest. Ophttalmol., Vis.Sci^ 1998, 30, 1726-1731.&lt;/p&gt;&lt;p&gt;Reynes R.I., Kronel G. Falbo A. et al. Ophtlalmologic safely of long-term hydroxychloroquine treatment. Arthritis Rheum , 1979. 22, 832-836.&lt;/p&gt;&lt;p&gt;Reynes R.l. Ophtalmologic considerations in using antimalarials in the Uniled States. Lupus, 1996, 5, suppl 1, 73-74. 3S. Rynes R.Antimalarial drugs. In: Textbook of rheumatology, ed. W.Kelley, E.Harris, S.Ruddy, C.Sledge, W.B.Saunders. 1993. 731-742.&lt;/p&gt;&lt;p&gt;Royal College of OpIUtalmologists. Ocular toxicily and hydroxychloroquine. Guidelines for screening. 1998.&lt;/p&gt;&lt;p&gt;Rubin M.L., Thomas W.C. Diplopia and loss of accommodation due to chloroquine. Arthr. Rheum., 1970, 13, 75.&lt;/p&gt;&lt;p&gt;Ruiz R.S., Saatei O.A. Chloroquine and hydroxychloroquine relinopalhy: how to follow affected patients. Ann. Ophthalmol., 1991, 23, 290-291.&lt;/p&gt;&lt;p&gt;Sachs D.D., Hoban M.J. Engleinan E. Chorioretinopathy induced by chronic administration of chloroquine phosphate. Arthritis Rheum., 1962, 5, 318-319.&lt;/p&gt;&lt;p&gt;Sassman F.W., Cassidy J.T., Alpern М., Maaseidvaag Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine. Am. J. Ophtalmol., 1970, 71, 515-523.&lt;/p&gt;&lt;p&gt;Scherbel A.L., Mackenzie A.H., Nousek J.E., Aidjian M.Ocular lesions in rheumatoid arthritis and related disorders wilh particular reference to retinopalhy: a study of 741 patients treated with and without chloroquine drugs. N. Engl. J. Med. 1965, 273, 360-366.&lt;/p&gt;&lt;p&gt;Shipley M„ Silman A.Should patients on hydroxychloroquine have their eyes examined regularly? Bril. J.Rheumatol., 1997, 36, 514-515.&lt;/p&gt;&lt;p&gt;Tobin D.R., Krohel G.B., Reynes R.I.: Hydroxychloroquine. A seven-year experience. Arch. Ophtalmol., 1982, 100, 478.&lt;/p&gt;&lt;p&gt;Voipio H.Incidence of chloroquine relinopalhy. Acta Ophthalmol., 1966, 44, 349-354.&lt;/p&gt;&lt;p&gt;Vu B.L., Easterbrook М., Hovis J.K. Detection of color vision defects in chloroquine retinopalhy. Ophtalmol., 1999, 106, 17991803.&lt;/p&gt;&lt;p&gt;Wallace D.J.Antimalarial therapies. In: Wallace D.J., Hahn B. H., eds. Dubois'Lupus Erythematosus, 4th edn. Philadelphia: Lea&amp;amp;Febiger, 1993, 563-573.&lt;/p&gt;&lt;p&gt;Weise E.E., Yarronzzi L.A. Ring maculopathies mimicking chloroquine retinopalhy. Am.J.Ophlalmol., 1974, 78, 204-210.&lt;/p&gt;&lt;p&gt;Young , Rardin Т., Lankford B. et al. The apparent elimination of chloroquine retinopathy. Arthr. Rheum., 1974, 15, 464.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
